Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S' Partner in North America, Merck, Reports Phase III Data on Investigational Grass Sublingual Allergy Immunotherapy Tablet


Saturday, 9 Nov 2013 12:36pm EST 

Alk Abello A/S announced that the Company's Partner for North America, Merck has reported data from a pivotal Phase III clinical trial with its investigational grass sublingual allergy immunotherapy (AIT) tablet. The trial met its primary endpoint and the results showed that the use of grass AIT tablets significantly reduced the total combined score that measured nasal and eye symptoms and use of rescue allergy medicines, compared to placebo, in grass-allergic patients. In January 2013, Merck submitted a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for the disease-modifying grass AIT tablet and the regulatory review is currently ongoing. The product is marketed as GRAZAX in Europe. 

Company Quote

733.0
3.0 +0.41%
5:15am EDT